(NASDAQ: AMGN) Amgen's forecast annual revenue growth rate of 2.43% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Amgen's revenue in 2025 is $34,126,000,000.On average, 11 Wall Street analysts forecast AMGN's revenue for 2025 to be $18,926,435,889,476, with the lowest AMGN revenue forecast at $18,568,605,372,894, and the highest AMGN revenue forecast at $19,188,042,820,830. On average, 11 Wall Street analysts forecast AMGN's revenue for 2026 to be $19,207,138,915,905, with the lowest AMGN revenue forecast at $18,710,269,426,742, and the highest AMGN revenue forecast at $20,026,303,537,429.
In 2027, AMGN is forecast to generate $19,772,250,301,621 in revenue, with the lowest revenue forecast at $18,951,452,128,910 and the highest revenue forecast at $21,135,288,530,318.